丨 2025年8月8日星期五丨NO.1信达生物上半年产品收入增长超过35%8月7日,信达生物公告,2025年上半年共取得总产品收入超52亿元,同比保持35%以上的强劲增长。其中,2025年第二季度总产品收入超过27亿元,同比增长超过30%,该增长得益于肿瘤和综合管线双轮驱动共同发力。点评:公司的业绩增长得益于肿瘤和综合管线双轮驱动,显示出公司在研发和市场拓展方面的强劲实力,为未来持续增长奠定了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.